- Home
- COLL vs IBTA Comparison
COLL vs IBTA Comparison
Compare COLL & IBTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- IBTA
- Stock Information
- Founded
- COLL 2002
- IBTA 2011
- Country
- COLL United States
- IBTA United States
- Employees
- COLL N/A
- IBTA N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- IBTA
- Sector
- COLL Health Care
- IBTA
- Exchange
- COLL Nasdaq
- IBTA Nasdaq
- Market Cap
- COLL 958.8M
- IBTA 892.4M
- IPO Year
- COLL 2015
- IBTA 2024
- Fundamental
- Price
- COLL $31.60
- IBTA $36.80
- Analyst Decision
- COLL Strong Buy
- IBTA Buy
- Analyst Count
- COLL 4
- IBTA 10
- Target Price
- COLL $43.75
- IBTA $74.60
- AVG Volume (30 Days)
- COLL 291.1K
- IBTA 342.2K
- Earning Date
- COLL 08-07-2025
- IBTA 08-13-2025
- Dividend Yield
- COLL N/A
- IBTA N/A
- EPS Growth
- COLL N/A
- IBTA 24.66
- EPS
- COLL 1.25
- IBTA 2.03
- Revenue
- COLL $664,283,000.00
- IBTA $369,501,000.00
- Revenue This Year
- COLL $20.23
- IBTA $6.89
- Revenue Next Year
- COLL $3.82
- IBTA $15.55
- P/E Ratio
- COLL $25.23
- IBTA $18.17
- Revenue Growth
- COLL 17.17
- IBTA 7.20
- 52 Week Low
- COLL $23.23
- IBTA $31.40
- 52 Week High
- COLL $42.29
- IBTA $79.80
- Technical
- Relative Strength Index (RSI)
- COLL 61.58
- IBTA N/A
- Support Level
- COLL $31.53
- IBTA N/A
- Resistance Level
- COLL $32.95
- IBTA N/A
- Average True Range (ATR)
- COLL 0.88
- IBTA 0.00
- MACD
- COLL 0.06
- IBTA 0.00
- Stochastic Oscillator
- COLL 73.51
- IBTA 0.00
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).